ANDROGEN RECEPTOR SIGNALING REDUCES DIRECT CYTOTOXICITY OF BACILLUS CALMETTE-GUERIN (BCG) IN BLADDER CANCER CELLS VIA MODULATING RAB27B

被引：0
|
作者：
Mizushima, Taichi
Jiang, Guiyang
Kawahara, Takashi
Li, Peng
Han, Bin
Inoue, Satoshi
Ide, Hiroki
Jalalizadeh, Mehrsa
Uemura, Hiroji
Reis, Leonardo
Miyamoto, Hiroshi
机构：
来源：
JOURNAL OF UROLOGY | 2019年 / 201卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP57-08
引用
收藏
页码：E815 / E816
页数：2
相关论文
共 40 条
  • [31] Long term prophylaxis with mitomycin C (MMC) significantly reduces tumor recurrence compared to short term prophylaxis with MMC or bacillus Calmette-Guerin (BCG) in non muscle-invasive bladder cancer (NMIBC)
    Friedrich, MG
    Conrad, S
    Pichlmeier, U
    Wolf, N
    Schwaibold, H
    Huland, H
    JOURNAL OF UROLOGY, 2006, 175 (04): : 270 - 270
  • [32] Preliminary results of phase II trial of concomitant administration of intravesical reduced dose Bacillus Calmette-Guerin (BCG) and interferon a 2B (IFN) in the prevention of recurrence of superficial bladder cancer.
    Bazarbashi, S
    Raja, M
    Kattan, S
    Rahal, M
    El-Weshi, A
    Pai, C
    Rehman, K
    Aslam, M
    Othman, K
    Hanash, K
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 435S - 435S
  • [33] Cancer Stem Cells (CSC) Responses and Toll-Like Receptors (TLRs) and p53 Signaling Pathway: Effects of Bacillus Calmette-Guerin (BCG) and P-MAPA Immunotherapies in Non-Muscle Invasive Bladder Cancer (NMIBC)
    Favaro, W. J.
    Billis, A.
    Seiva, F. R. F.
    Nunes, I. S.
    Duran, N.
    LABORATORY INVESTIGATION, 2013, 93 : 210A - 210A
  • [34] Cancer Stem Cells (CSC) Responses and Toll-Like Receptors (TLRs) and p53 Signaling Pathway: Effects of Bacillus Calmette-Guerin (BCG) and P-MAPA Immunotherapies in Non-Muscle Invasive Bladder Cancer (NMIBC)
    Favaro, W. J.
    Billis, A.
    Seiva, F. R. F.
    Nunes, I. S.
    Duran, N.
    MODERN PATHOLOGY, 2013, 26 : 210A - 210A
  • [35] Mycobacterium bovis bacillus Calmette-Guerin induces CCL5 secretion via the toll-like receptor 2-NF-κB and -Jun N-terminal kinase signaling pathways
    Mendez-Samperio, Patricia
    Trejo, Artemisa
    Perez, Aline
    CLINICAL AND VACCINE IMMUNOLOGY, 2008, 15 (02) : 277 - 283
  • [36] Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer
    Navai, Neema
    Benedict, William F.
    Zhang, Guangcheng
    Abraham, Alice
    Ainslie, Nancy
    Shah, Jay B.
    Grossman, H. Barton
    Kamat, Ashish M.
    Dinney, Colin P. N.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (12) : 4110 - 4114
  • [37] Randomized comparator-controlled study evaluating efficacy and safety of pembrolizumab plus Bacillus Calmette-Guerin (BCG) in patients with high-risk nonmuscle-invasive bladder cancer (HR NMIBC): KEYNOTE-676 cohort B.
    Kamat, Ashish M.
    Shariat, Shahrokh
    Steinberg, Gary D.
    Alanee, Shaheen Riadh
    Nishiyama, Hiroyuki
    Nam, Kijoeng
    Kapadia, Ekta
    Shore, Neal D.
    Hahn, Noah M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [38] KEYNOTE-676 cohort B: Randomized comparator-controlled cohort to evaluate efficacy and safety of pembrolizumab (pembro) plus bacillus Calmette-Guerin (BCG) in patients with high-risk BCG treatment-naive non-muscle invasive bladder cancer (HR NMIBC)
    Shariat, S. F.
    Steinberg, G.
    Kamat, A. M.
    Shore, N. D.
    Alanee, S.
    Nishiyama, H.
    Nam, K.
    Godwin, J. L.
    Kapadia, E.
    Hahn, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S723 - S723
  • [39] PEMBROLIZUMAB (PEMBRO) FOR PATIENTS (PTS) WITH HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (HR NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG): EFFICACY AND EVALUATION OF SUBSEQUENT CYSTECTOMY FROM COHORT B OF THE PHASE 2 KEYNOTE-057 STUDY
    Singer, Eric
    Necchi, Andrea
    Roumiguie, Mathieu
    Esen, Ahmet Adil
    Lebret, Thierry
    de Wit, Ronald
    Bajorin, Dean F.
    Krieger, Laurence E. M.
    Kandori, Shuya
    Uchio, Edward M.
    Seo, Ho Kyung
    Boormans, Joost
    Kamat, Ashish M.
    Grivas, Petros
    Nishiyama, Hiroyuki
    Baranwal, Pranshu
    Kapadia, Ekta
    Van den Sigtenhorst-Fijlstra, Margot
    Kulkarni, Girish S.
    Shore, Neal D.
    JOURNAL OF UROLOGY, 2023, 209 : E1195 - E1195
  • [40] THOR-2 cohort 1: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts) with high-risk non emuscle-invasive bladder cancer (HR NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guerin (BCG) treatment
    Catto, J. W. F.
    Tran, B.
    Roupret, M.
    Gschwend, J. E.
    Loriot, Y.
    Nishiyama, H.
    Palou, J.
    Daneshmand, S.
    Hussain, S. A.
    Cutuli, H. J.
    Procopio, G.
    Guadalupi, V.
    Vasdev, N.
    Naini, V.
    Crow, L.
    Triantos, S.
    Baig, M.
    Steinberg, G. D.
    ANNALS OF ONCOLOGY, 2023, 34 : S1341 - S1342
1234